Clinical Trial Search

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants

Primary: Participants With Urine Cultures With Bacteriuria (>100,000 Cfu/ml or >=100,000 Cfu/ml) Plus Pyuria (Any WBC) — 26; 32; 21; 27 participants

Primary: Post-operative Urinary Tract Infection — 19; 20 Participants

Primary: Urinary Tract Infection — 11; 12 UTI

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants

Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants

Primary: Incidence of Post-operative UTI Following the Placement of Sub-urethral Sling for the Treatment of Stress Urinary Incontinence — 13; 24 participants

Primary: Number of Urine Cultures Collected Out of the Total Number Expected to be Collected. — 81; 74; 85; 73 Urine cultures

Primary: Changes to the Urinary Microbiota — 3; 2; 1 participants

Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548

Primary: Urinary Tract Infections — 18; 10 participants

Primary: Participants With Clinically-diagnosed and Treated UTI's. — 15; 30 participants

Primary: Change in Vaginal Microbiota — 2.75 change in percent relative abundance

Primary: Incidence of Urinary Tract Infection — 7; 13 participants

Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97

Primary: Number of Participants With Overall Success — 36; 17 Participants

Primary: Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI — 101; 119 days

Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…

Primary: Microbiological Response Assessment Profile — 58; 63 Participants

Primary: Eligible Subjects That Were Enrolled in the Study — 70 Participants

Primary: UTI Incidence as Described Below, Over the 16 Week Study Period Following Randomization, in the LACTIN-V Treatment Group (Group A) as Compared to the Placebo Group…

Primary: Occurrence of Symptomatic Urinary Tract Infections (UTIs) — 19; 20; 2; 0 participants — p=0.0383

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: UTI — 15; 14 Participants — p=0.84

Primary: Number of Participant With Urinary Tract Infection — 12; 13 Participants

Primary: Clinical Cure — 140; 123; 10; 27 participants

Primary: Number of Participants With Microbiological Response at the Test of Cure (ToC) Visit — 10; 10; 1; 18 Participants

Primary: The Distribution of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan — 12; 22; 111; 109 Participants — p=0.16